Literature DB >> 10064646

Betahistine increases vestibular blood flow.

J K Dziadziola1, E L Laurikainen, J D Rachel, W S Quirk.   

Abstract

Betahistine is used for treatment of several vestibular disorders. Despite the accepted use of this histamine-like substance, its mechanism of action is not well understood. The purpose of this study was to assess the possibility that one of the activities of betahistine is increasing blood flow in the peripheral vestibular end organs. Using a novel surgical approach, we identified the posterior semicircular canal ampulla of guinea pigs and placed a laser Doppler probe in position to obtain blood flow measurements from the posterior semicircular canal ampulla. Blood pressure, heart rate, and vestibular blood flow were continuously recorded. Concentration-response curves were obtained for betahistine (2.5, 5, 7.5, and 10 mg/kg) and control-vehicle (0.15 mol/L NaCl) infusions. A separate group of subjects was pretreated with the competitive selective H3 agonist, thioperimide maleate, before betahistine treatment. Increases in vestibular blood flow and decreases in blood pressure were observed in response to betahistine infusions. Pretreatment with thioperamide maleate abolished these changes at low doses of betahistine and attenuated the responses at higher doses of betahistine. These results show that betahistine administration induces increases in vestibular blood flow. These findings support the potential use of betahistine for treatment of vestibular disorders, which may be caused by compromised circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064646     DOI: 10.1016/S0194-5998(99)70283-4

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  16 in total

1.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Correspondence (reply): In Reply.

Authors:  Michael Strupp
Journal:  Dtsch Arztebl Int       Date:  2008-10-24       Impact factor: 5.594

3.  Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.

Authors:  Jolene Zheng; Joseph R Vasselli; Jason F King; Michael L King; Wenqian We; Zachary Fitzpatrick; William D Johnson; John W Finley; Roy J Martin; Michael J Keenan; Frederic M Enright; Frank L Greenway
Journal:  Am J Ther       Date:  2016 Nov/Dec       Impact factor: 2.688

4.  Betahistine: a retrospective synopsis of safety data.

Authors:  Sabine Jeck-Thole; Wolfgang Wagner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Selective abolition of the vestibular-ocular reflex by sedative drugs.

Authors:  Sarah Anne Morrow; G Bryan Young
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 6.  Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

Authors:  M Lacour; O Sterkers
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Allergy and Ménière's disease.

Authors:  M Jennifer Derebery; Karen I Berliner
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

Review 8.  Pharmacological treatment of vertigo.

Authors:  Timothy C Hain; Mohammed Uddin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

Authors:  Michael Strupp; Matthew J Thurtell; Aasef G Shaikh; Thomas Brandt; David S Zee; R John Leigh
Journal:  J Neurol       Date:  2011-04-02       Impact factor: 4.849

10.  Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.

Authors:  D Monzani; M R Barillari; M Alicandri Ciufelli; E Aggazzotti Cavazza; V Neri; L Presutti; E Genovese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-12       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.